LONDON: RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, announced investments in new private portfolio companies, Mirador Therapeutics and Santa Ana Bio.
RTW, alongside other investment vehicles managed by RTW Investments, LP, participated in Mirador’s Series A financing round that raised over $400 million for its launch in March.
Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Josh Kennedy-Smith, Partner and Research Analyst at the Investment Manager said, “We are thrilled to support Mirador Therapeutics whose team we worked with when they led Prometheus Biosciences through to its acquisition by Merck for $10.8 billion in 2023. We have every confidence in their track record to develop the next wave of precision medicines in immunology and inflammation.”
The Company, alongside other investment vehicles managed by the Investment Manager, also participated in Santa Ana’s Series A financing round that raised $168 million in May.
Santa Ana Bio is a biotechnology company developing a pipeline of innovative therapeutics and leveraging its multi-omics platform to unlock the full potential of precision medicines. Santa Ana’s platform, based on transcriptomics and proteomics, addresses the limitations of today’s commercial therapeutics.
Josh Kennedy-Smith said, “We’re excited to support Santa Ana as they advance their broad pipeline of precision, next-generation antibodies for autoimmune diseases into clinical development.”
Commenting on recent activity, Chief Investment Officer, Rod Wong, said, “We are active again in private investing and seeing a lot of opportunity. After a couple of years of slower deployment as we focused on opportunities in the public market, we now expect to head back to our normal pace of about a dozen private deals per year, especially if the IPO window continues to trend positively.”
RTW BIO completes investment in Arix Bioscience ahead of merger